Bioresorbable scaffold implantation in STEMI patients: 5 years imaging subanalysis of PRAGUE-19 study.
Bioresorbable scaffold
Long-term follow-up
Optical coherence tomography
Quantitative coronary angiography
STEMI
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
30 01 2020
30 01 2020
Historique:
received:
09
06
2019
accepted:
14
01
2020
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Bioresorbable scaffold (BRS) Absorb™ clinical use has been stopped due to higher rate of device thrombosis. Scaffold struts persist longer than 2 years in the vessel wall. Second generation devices are being developed. This study evaluates long-term invasive imaging in STEMI patients. PRAGUE-19 study is an academic study enrolling consecutive STEMI patients with intention to implant Absorb™ BRS. A total of 83 STEMI patients between December 2012 and March 2014 fulfilled entry criteria. Coronary angiography and optical coherence tomography at 5 year follow-up was performed in 25 patients. Primary combined clinical endpoint (death, myocardial infarction or target vessel revascularization) occurred in 12.6% during the five-year follow-up with overall mortality 6.3%. Definite scaffold thrombosis occurred in 2 patients in the early phase after BRS implantation. Quantitative coronary angiography after 5 years demonstrated low late lumen loss of 0.11 ± 0.35 mm with binary restenosis rate of 0%. Optical coherence tomography demonstrated complete resorption of scaffold struts and mean lumen diameter of 3.25 ± 0.30 and 3.22 ± 0.49 (P = 0.73) at baseline and after 5 years, respectively. Three patients developed small coronary artery aneurysm in the treated segment. Invasive imaging results 5 years after BRS implantation in STEMI showed complete resorption of scaffold struts and stable lumen vessel diameter. Trial registration ISRCTN43696201 (retrospectivelly registred, June 7th, 2019). https://www.isrctn.com/ISRCTN43696201.
Sections du résumé
BACKGROUND
Bioresorbable scaffold (BRS) Absorb™ clinical use has been stopped due to higher rate of device thrombosis. Scaffold struts persist longer than 2 years in the vessel wall. Second generation devices are being developed. This study evaluates long-term invasive imaging in STEMI patients.
METHODS
PRAGUE-19 study is an academic study enrolling consecutive STEMI patients with intention to implant Absorb™ BRS. A total of 83 STEMI patients between December 2012 and March 2014 fulfilled entry criteria. Coronary angiography and optical coherence tomography at 5 year follow-up was performed in 25 patients.
RESULTS
Primary combined clinical endpoint (death, myocardial infarction or target vessel revascularization) occurred in 12.6% during the five-year follow-up with overall mortality 6.3%. Definite scaffold thrombosis occurred in 2 patients in the early phase after BRS implantation. Quantitative coronary angiography after 5 years demonstrated low late lumen loss of 0.11 ± 0.35 mm with binary restenosis rate of 0%. Optical coherence tomography demonstrated complete resorption of scaffold struts and mean lumen diameter of 3.25 ± 0.30 and 3.22 ± 0.49 (P = 0.73) at baseline and after 5 years, respectively. Three patients developed small coronary artery aneurysm in the treated segment.
CONCLUSION
Invasive imaging results 5 years after BRS implantation in STEMI showed complete resorption of scaffold struts and stable lumen vessel diameter. Trial registration ISRCTN43696201 (retrospectivelly registred, June 7th, 2019). https://www.isrctn.com/ISRCTN43696201.
Identifiants
pubmed: 32000796
doi: 10.1186/s12967-020-02230-1
pii: 10.1186/s12967-020-02230-1
pmc: PMC6993315
doi:
Banques de données
ISRCTN
['ISRCTN43696201']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Références
EuroIntervention. 2010 Aug;6(3):371-9
pubmed: 20884417
Circulation. 2015 Feb 24;131(8):764-7
pubmed: 25712060
Eur Heart J Cardiovasc Imaging. 2013 Sep;14(9):865-75
pubmed: 23291393
EuroIntervention. 2018 Jan 20;13(13):1565-1573
pubmed: 28671552
JACC Cardiovasc Interv. 2008 Feb;1(1):14-21
pubmed: 19393139
Heart Vessels. 2016 Jun;31(6):841-5
pubmed: 25896128
Circulation. 2018 Jan 30;137(5):464-479
pubmed: 29089314
Catheter Cardiovasc Interv. 2018 Sep 1;92(3):E235-E245
pubmed: 29164770
JACC Cardiovasc Interv. 2017 Apr 24;10(8):786-795
pubmed: 28427595
Eur Heart J. 2019 Jan 7;40(2):167-176
pubmed: 30520980
Lancet. 2018 Oct 27;392(10157):1530-1540
pubmed: 30266412
JACC Cardiovasc Interv. 2017 Jan 23;10(2):200-202
pubmed: 28040446
Expert Rev Med Devices. 2015;12(5):545-57
pubmed: 26305838
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):189-197
pubmed: 25616924
Eur Heart J Cardiovasc Imaging. 2015 Jan;16(1):23-8
pubmed: 25342855
Int J Cardiol. 2016 Jul 1;214:483-4
pubmed: 27096965
J Am Coll Cardiol. 2016 Feb 23;67(7):766-76
pubmed: 26892411
J Am Heart Assoc. 2019 Apr 2;8(7):e011817
pubmed: 30905253
EuroIntervention. 2019 Feb 20;14(14):1435-1534
pubmed: 30667361
EuroIntervention. 2016 Jan 22;11(9):996-1003
pubmed: 25349042
JACC Cardiovasc Interv. 2017 Jan 23;10(2):e11-e13
pubmed: 28040440
Eur Heart J. 2016 Jan 14;37(3):229-40
pubmed: 26405232
JACC Cardiovasc Imaging. 2014 Nov;7(11):1130-48
pubmed: 25459595
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
EuroIntervention. 2017 Dec 8;13(12):e1483-e1486
pubmed: 28760724
Lancet. 2017 Aug 19;390(10096):760-772
pubmed: 28732815
EuroIntervention. 2018 Dec 07;14(11):e1224-e1226
pubmed: 30398967
EuroIntervention. 2016 May 17;12(1):23-9
pubmed: 27173858
Eur Heart J. 2016 Jul 07;37(26):2040-9
pubmed: 26543048
Eur Heart J. 2014 Mar;35(12):787-94
pubmed: 24419808